Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
Completed
NCT Number: NCT02069639
TARC After alloSCT in Hodgkin's Lymphoma
Relapsed and refractory Hodgkin's lymphoma (HL) patients may experience long-term survival after allogeneic transplant (alloSCT), but disease recurrence represents the main cause of treatment failure. PET (positron-emission tomography) -positive patients after alloSCT have a dismal outcome. Serum TARC (thymus and activation-regulated chemokine) is produced by Reed-Sternberg cells and may be a marker of disease. Our study was aimed at assessing whether TARC levels after alloSCT were correlated to disease status and whether TARC monitoring could increase the ability to predict relapse.
Completed
Looking for future studies?
Notify MeKey information
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Hodgkin's lymphoma patients who underwent an alloSCT at Fondazione IRCCS Istituto Nazionale dei Tumori and who were monitored by PET and TARC before and after alloSCT from 2009
Exclusion criteria
- Hodgkin's lymphoma patients who underwent an alloSCT who were not monitored by PET or/and TARC
Treatment and study plan
No treatment
OtherPrimary outcomes
-
Correlation between disease status and serum TARC level
Time frame: One year after transplant
Serum TARC level was measured before alloSCT in Hodgkin's lymphoma patients and after alloSCT. The median time interval after alloSCT was 47 days. PFS was estimated at one year based on TARC value.
Secondary outcomes
-
The correlation between TARC levels and PET results after alloSCT
Time frame: Before alloSCT, monthly during the first 6 months after alloSCT and every 2 months until 2 years of follow-up, then at the time of clinical check-up (usually every 6 months)
We selected TARC values done on the days of PET to assess a cut-off value of TARC that was correlated to a positive or negative PET
Sponsors and collaborators
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Registry information
Official study title
Serum Thymus and Activation-regulated Chemokine (TARC) Level Monitoring May Predict Disease Relapse Detected by PET Scan After Reduced Intensity Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma Patients
Acronym: TARC
Important dates
- Study start
- 2013
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Feb 24, 2014
- Registry last updated
- Feb 24, 2014
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.